Ocrelizumab, a monoclonal antibody, has been granted approval for the treatment of both RRMS and primary‐progressive multiple sclerosis (PPMS) through its targeted depletion of CD20‐positive B cells. Here, MS4A1 is linked to primary progressive multiple sclerosis.